Young Choi, MD
Research & Publications
Biography
Locations
Research Summary
One of the major treatment tools for breast cancer is antiestrogen treatment against estrogen Receptor-alpha (ERa) and it is the accepted therapeutic prognostic marker to predict the response of an individual breast cancer to antiestrogen therapy. However, approximately 50% of ERa positive breast cancers are de novo resistant to selective estrogen receptor modulators (SERMs) and many breast cancers acquire tamoxifen (Tam) resistance during progression due to de novo and acquired resistance to tamoxifen and seriously limit the efficacy of this treatment. The reasons for this lack of response are poorly understood. One of the mechanisms may be related to the second receptor ER-beta. I am pursuing the receptor to determine a possible targeted therapy for breast cancer.
Specialized Terms: Immunopathology; Molecular Pathology; Cytopathology and Clinical Pathology; Breast Cancer;
Extensive Research Description
Coauthors
Research Interests
Breast Neoplasms; Pathology; Medical Laboratory Science; Selective Estrogen Receptor Modulators; Estrogen Receptor alpha
Selected Publications
- Evidence-based medical practice and the outcomes of education.ChoiY, Krause L. Evidence-based medical practice and the outcomes of education. Modern Pathol 2011; 24:129A
- ERß1, AIB-1 and TIF-2 expression in breast cancer-associated myofibroblasts.Choi Y. ERß1, AIB-1 and TIF-2 expression in breast cancer-associated myofibroblasts. Modern Pathol 2010; 23:40A.
- Tissue –specific expression of estrogen receptor-ß wild type and its isoforms.Choi Y. Tissue –specific expression of estrogen receptor-ß wild type and its isoforms. Arch Pathol Lab Med 2009; 133:1632.
- Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinomaChoi YJ, M Pinto M, Hao L, K Riba A. Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinoma Modern Pathology 2008, 21: 1224-1237. PMID: 18587329, DOI: 10.1038/modpathol.2008.106.
- Estrogen receptor beta in breast cancer: associations between ERbeta, hormonal receptors, and other prognostic biomarkers.Choi Y, Pinto M. Estrogen receptor beta in breast cancer: associations between ERbeta, hormonal receptors, and other prognostic biomarkers. Applied Immunohistochemistry & Molecular Morphology : AIMM / Official Publication Of The Society For Applied Immunohistochemistry 2005, 13: 19-24. PMID: 15722789, DOI: 10.1097/00129039-200503000-00004.
- Co-expression of ER-alpha and beta and over-expression of ER-beta in recurrent and metastatic breast cancer.Choi Y. Co-expression of ER-alpha and beta and over-expression of ER-beta in recurrent and metastatic breast cancer. Lab Investigation 2004 84:26A.
- Diets and growth factors in breast cancer.Choi Y. Diets and growth factors in breast cancer. J of KAMA 2003, 9:27-34
- Human papilloma virus, vulvar dystrophy, and vulvar carcinoma: differential expression of human papillomavirus and vulvar dystrophy in the presence and absence of squamous cell carcinoma of the vulva.Sagerman PM, Choi YJ, Hu Y, Niedt GW. Human papilloma virus, vulvar dystrophy, and vulvar carcinoma: differential expression of human papillomavirus and vulvar dystrophy in the presence and absence of squamous cell carcinoma of the vulva. Gynecologic Oncology 1996, 61: 328-32. PMID: 8641610, DOI: 10.1006/gyno.1996.0151.
- In situ hybridization using a biotinylated DNA probe on formalin-fixed liver biopsies with hepatitis B virus infections: in situ hybridization superior to immunochemistry.Choi YJ. In situ hybridization using a biotinylated DNA probe on formalin-fixed liver biopsies with hepatitis B virus infections: in situ hybridization superior to immunochemistry. Modern Pathology 1990, 3: 343-7. PMID: 2194215.